Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

16 bioc


Published on

  • Be the first to comment

  • Be the first to like this

16 bioc

  1. 1. The  CEE  Solu+on   Personalized  Medicine  from  a  Liquid  Biopsy  
  2. 2. Forward–Looking  Statements   This  presenta+on  contains,  and  any  accompanying  oral  presenta+on  would  no  doubt   contain,  forward-­‐looking  statements,  within  the  meaning  of  the  Private  Securi+es   Li+ga+on  Reform  Act  of  1995,  regarding  us  (Biocept,  Inc.)  and  our  business.     Forward-­‐looking  statements  include  all  statements  that  are  not  historical  facts  and   generally  can  be  iden+fied  by  terms  such  as  an+cipates,  believes,  could,  es+mates,   expects,  intends,  may,  plans,  poten+al,  predicts,  projects,  should,  will,  would,  or  the   nega+ve  of  those  terms  and  similar  expressions.   Forward-­‐looking  statements  involve  known  and  unknown  risks,  uncertain+es  and   other  factors  which  may  cause  our  actual  results,  performance  or  achievements  to   be  materially  different  from  any  future  results,  performance  or  achievements   expressed  or  implied  by  the  forward-­‐looking  statements.    For  details  about  these   risks,  please  see  our  SEC  filings.   All  forward  looking  statements  contained  in  this  presenta+on  speak  only  as  of  the   date  hereof,  and  except  as  required  by  law,  we  assume  no  obliga+on  to  update  these   forward-­‐looking  statements  whether  as  a  result  of  any  new  informa+on,  future   events,  changed  circumstances  or  otherwise.   2  
  3. 3.  Business  Overview   CLIA  facility  in     San  Diego,  CA   Genomic  test  results   sent  to  physicians                                                                                          R&D   Clinical   Development   CLIA  Lab   R  and  D,  test  kits     manufactured  and     samples  analyzed   Manufacturing   3  
  4. 4. Investment  Highlights   •  OncoCEE™:  measures  circula+ng  tumor  cells  (CTCs)     •  OncoCEE-­‐BR™  :  first  commercialized  test  for  breast  cancer     •  CEE-­‐Selector™:  plaorm  expansion  for  muta+on  analysis   •  Robust  test  pipeline  focused  on  solid  tumor  genomic  diagnos+cs   including  lung,  breast,  colon,  prostate  and  melanoma   •  Established,  cer+fied  and  scalable  CLIA  lab   •  Clear  path  to  market  penetra+on   •  Established  research  collabora+ons  and  strategic  partnerships   •  IPO  completed  February  2014;  gross  proceeds  of  $19  million   4   Commercial  stage  cancer  diagnos0cs  company  with  ground-­‐breaking   technology  pla9orm  u0lizing  a  simple  blood  test  
  5. 5. Mul+faceted  Growth  Strategy   •  Commercializa+on   –  Clinical,  Commercial     –  Biopharma   –  Partnerships   •  Test  Menu  Build  Out   –  test  valida+on     –  Clinical  u+lity  studies     –  Plaorm  expansion   •  Opera+onal  Efficiency   –  Automa+on   –  Process  improvements   –  Increase  Gross  Margin   5  
  6. 6. Biocept  Execu+ve  Team   6   Michael  Nall                 President  and  CEO     Lyle  Arnold,  Ph.D. SVP,  R&D  and  CSO   Farideh  Bischoff,  Ph.D.     VP  TranslaEonal  Research  and   Clinical  Development   Bill  Kachioff                                 SVP,  Finance  and  CFO   David  Hale   ExecuEve  Chairman   •   More  than  25  years  in  healthcare  sales,  marke+ng  and  commercial  opera+ons   •   14  years  in  cancer  diagnos+cs  and  genomics   •   Most  recently  GM  N.  American  Sales  and  Marke+ng  for  Clarient,  a  GE  Healthcare  Company   •   Senior  R&D  Leadership  at  Gen-­‐Probe,  Incyte  Genomics,  Genta   •   Founder/  Co-­‐founder  Oasis  Biosciences,  Molecular  Biosystems,  Aegea  Biotechnologies   •   Former  faculty  member,  UCSD  School  of  Medicine  and  member,  UCSD  Cancer  Center   •   39  issued  US  and  140  issued  and  pending  patents  worldwide   •   Former  Associate  Professor  and  member,  Cancer  Center  at  Baylor  College  of  Medicine   •   Postdoc  at  MD  Anderson  and  Baylor  College  of  Medicine   •   More  than  130  peer  reviewed  papers  and  book  chapters   •   Chairman  and  CEO  of  Hale  BioPharma  Ventures  with  over  35  years  as  a  healthcare  visionary   •   Chairman  of  Santarus  (acquired  by  Salix),  Conatus,  Micromet  (acquired  by  Amgen),  and     SkinMedica      (acquired  by  Allergan)   •   CEO  of  Hybritech  (acquired  by  Lilly)  ,  Gensia  (acquired  by  Teva)     •   More  than  20  years  life  sciences  experience   •   14  years  of  experience  in  public  company  finance   •   Abboj  Labs,  Cutera,  Coulter  Pharmacue+cal,    Althea,  Vivus   •   Diverse  finance  and  opera+ons  management  experience     Raaj  Trivedi     VP  Commercial  OperaEons   •   More  than  15  years  in  healthcare  sales,  marke+ng  and  business  development     •   Served  as  VP  of  Marke+ng  and  then  VP  of  Business  Development  at    Clarient   •   Life  Technologies  Commercial  Leader  for  Oncomine  Biomarker  Discovery  Plaorms  
  7. 7. US  Market  Opportunity   7   Cancer   Type   New   Cases/   Year   Living  with   Cancer   Deaths/   Year   Breast 232,340 2,829,041 39,620 Prostate 238,590 2,617,682 29,720 Lung 228,190 399,431 159,480 Colorectal 142,820 1,154,481 50,830 Melanoma 76,690 921,780 9,480 Total 918,630 7,922,415 289,130 *  Incidence,  prevalence  and  deaths  data  provided  by  Na+onal  Cancer  Ins+tute:      hjp://  
  8. 8. Molecular  Cancer  Tes+ng  Market   8   *GEN  Magazine,  Bold  Predic+on  for  Future  Cancer  Tests                  *Frost  and  Sullivan  –  Market  Research  2011   **Jain  Pharma  Biotech  June  2011   CAGR   22.9%  for  US   0   0.5   1   1.5   2   2.5   3   2010   2015   2017   N.  America*   Global**   $  Billions   Market  Characteris9cs:   •  Increased  reliance  on  molecular  diagnos+cs  for  treatment  decisions   •  Expanding  use  of  targeted  therapies   •  Greater  sophis+ca+on  of  oncology  diagnos+cs   •  Limited  by  need  for  tumor  +ssue  
  9. 9. Limita+ons  of  Tissue  Biopsy   Cancer  is  a  heterogeneous  disease   –  Molecular  proper+es  differ  within  a  tumor   –  Primary  tumor  biopsy  may  not  reflect  current  disease  condi+on   –  Therapy  causes  changes  in  tumor  cells   Biopsy  is  invasive   –  May  not  be  feasible  based  on  pa+ent  condi+on  or  tumor  accessibility   –  Imprac+cal  for  periodic  monitoring    for  progression  /  recurrence   Biopsy  +ssue  is  limited   –  Greater  demand  due  to  molecular  profiling   –  Surgery  is  costly       9   Liquid  Biopsy  Addresses  Limita9ons  in  Standard  of  Care  
  10. 10. New  Molecular  Paradigm  –  Liquid  Biopsy     •  ctDNA  -­‐  CTCs  –  Circula+ng  Tumor  Cells,  cell  free  Circula+ng  tumor  DNA   •  ctDNA:  demonstrated  surrogate  for  tumor  +ssue  biopsy   •  Can  be  captured  and  characterized  for  biomarkers,  similar  to  +ssue   •  Liquid  biopsy  repeatable  throughout  treatment,  par+cularly  when  +ssue  unavailable     •  66%  of  researchers  say  analysis  of  CTCs  will  be  standard  of  care  in  the  next  4  years*     10   *CTC  industry  overview  –  Hanson  and  Wade    2013   Solid  tumors  shed   CTCs  and  ctDNA   into  blood   CTCs  and  ctDNA  travel   via  bloodstream   CTCs  &  ctDNA  analyzed  for   pa+ent  treatment   decisions   Breast  cancer  CTC  
  11. 11. OncoCEE™  Personalized  Genomic  Diagnos+cs   11      Personalized  Treatment   EGFR/ALK/ROS1    K-­‐ras    B-­‐raf    ZELBORAF®     (vemurafenib)      TARCEVA®  (erlo+nib)                                &        IRESSA®  (gefi+nib)  /        XALKORI  ®(crizo+nib)                    ERBITUX®                    (cetuximab)                                    &                    VECTIBIX®                          (panitumumab)                                                                                              HER2    HERCEPTIN®     (trastuzumab  )     The  Right  Therapy  for  the  Right  Pa9ent  at  the  Right  Time  OncoCEE-­‐BR™   Breast  Cancer      OncoCEE-­‐ME™   Melanoma    OncoCEE-­‐CR™   Colorectal  Cancer      OncoCEE-­‐LU™   Non-­‐small  Cell  Cancer    
  12. 12. Intellectual  Property   12   CEE-­‐SelectorTM   Muta+on  Analysis   Patent  pending   Biocept  Developed  SoluEons   Patented     CEE®   Microfluidic  Channel   CEE-­‐Sure™   Stability     Transport  Tube   Patent  pending   OncoCEE™   Chemistry:  An+body   Cocktail   Patent  pending   One  US  and  associated   foreign  patents  pending   Two  issued  US  patents  and   two  issued  foreign  patents;   mulEple  pending  US  and   foreign    patents   Two  US  and    associated   foreign  patents  pending  for   capture;  one  US  and   associated  foreign  patents   pending  for  detecEon   One  US  and  associated   foreign  patents  pending  
  13. 13. CEE-­‐Selector™  Plaorm   •  Allows  for  both  CTC  and  cell  free  ctDNA  analysis   •  Detects  1  muta+on  out  of  >10,000  normal  DNA   •  Works  with  various  nucleic  acid  targets  (DNA  and  RNA)   •  Compa+ble  with  sequencing  and  PCR  instruments   •  Mul+plexing  reduces  costs  and  enhances  reimbursement   •  Poten+al  applica+ons  in  all  stages  of  cancer     13   MutaEon  determinaEon  sensiEvity  10-­‐100x  beSer   than  compeEng  plaTorms* *  Biocept  internal  data  
  14. 14. 14   OncoCEE-­‐BR™   2015  2013   2014   Product  Valida9on-­‐  CLIA  Product  Development-­‐  R&D  and  TCD   OncoCEE-­‐BR™  (DTC)     OncoCEE-­‐PR™     OncoCEE-­‐LU™   OncoCEE-­‐CR™   OncoCEE-­‐ME™   Breast  cancer   Bone  marrow  for  breast  cancer   Prostate  cancer   Non-­‐small  cell  lung  cancer   Melanoma   Colorectal  cancer   HER2   OncoCEE-­‐GA™   Gastric  cancer   Product  Development  Pipeline   Muta9on  FISH   ER   PR   Pre-­‐2013  
  15. 15. 15   OncoCEE™  Product  Profiles   Product   Tumor  Type   OncoCEE™  CTC   CEE-­‐Selector™   OncoCEE-­‐BRTM                                      (launched)   Breast   Enumera+on    of  CTCs  ,     HER2,  ER,  PR   Currently  no  clinically  ac+onable   muta+ons  iden+fied   OncoCEE-­‐GATM   Gastric   Enumera+on  of  CTCs,  HER2   Currently  no  clinically  ac+onable   muta+ons  iden+fied     OncoCEE-­‐LUTM   Lung   Enumera+on  of  CTCs,  ALK,   ROS1   EGFR,  K-­‐ras,  B-­‐raf  muta+ons     OncoCEE-­‐CRTM   Colon   Enumera+on  of  CTCs,  EGFR   K-­‐ras,  B-­‐raf  muta+ons   OncoCEE-­‐PRTM   Prostate   Enumera+on  of  CTCs,  AR,  and   PTEN  dele+on  (blood  or  bone   marrow)   Currently  no  clinically  ac+onable   muta+ons  iden+fied   OncoCEE-­‐METM   Melanoma   Enumera+on  of  CTCs   B-­‐raf  and  N-­‐ras  muta+ons  
  16. 16. 16   Targeted  Commercializa+on  Strategy   •  Raise  awareness  of  the  value  of  ctDNA   •  Drive  OncoCEE  adop+on   – Market  directly  to  oncologists   – Develop  key  opinion  leader  speakers   •  Build  rela+onships  with  pa+ent  advocacy  groups     •  Publish  studies  with  major  cancer  centers   •  Par+cipate  in  medical  mee+ngs  /  symposia   •  Deepen  payor  rela+onships  and  expand  reimbursement  coverage   •  Expand  strategic  partnerships  with  pharma  and  biotech  for  personalized   diagnos+cs    
  17. 17. 17   Driving  Adop+on  for  Growth   12  Month  Commercial  Team   Build   •  Head  of  sales  and   marke+ng   •  Regionally  based  sales   team       •  Sales  team  for  Pharma     •  Managed  care  expert     •  Internal  marke+ng     •  Leverage  partner  sales   forces      
  18. 18. 18        Dana-­‐Farber   •  Metasta+c  Breast  Cancer  pa+ents  with  HER2  nega+ve  primary  biopsy   •  CTC  HER2  posi+ve  pa+ents,  as  detected  with  OncoCEE  BR,  placed  on  Hercep+n   •     Sponsored  by  Genentech   •     Results  expected  in  2014014        MD  Anderson   •     Recently  diagnosed  breast  cancer  pa+ents   •  15%  of  CTC  and  28%  of  DTCs  have  HER2  discordance  with  primary  tumor   •     Published  in  Cancer  Medicine  –  April  20132013  Other  studies   •  Four  addi+onal  peer  reviewed  published  studies  valida+ng  technology   •     Addi+onal  pending  studies  with  collaborators   •     Planned  study  in  Non  Small  Cell  Lung  Cancer   • Planned  study  in  Non  Small  Cell  Lung  Cancer   Clinical  U+lity  Studies  
  19. 19. Investment  Highlights   •  OncoCEE™:  measures  circula+ng  tumor  cells  (CTCs)     •  OncoCEE-­‐BR™  :  first  commercialized  test  for  breast  cancer     •  CEE-­‐Selector™:  plaorm  expansion  for  muta+on  analysis   •  Robust  test  pipeline  focused  on  solid  tumor  genomic  diagnos+cs   including  lung,  breast,  colon,  prostate  and  melanoma   •  Established,  cer+fied  and  scalable  CLIA  lab   •  Clear  path  to  market  penetra+on   •  Established  research  collabora+ons  and  strategic  partnerships   •  IPO  completed  February  2014;  gross  proceeds  of  $19  million   19   Commercial  stage  cancer  diagnos0cs  company  with  ground-­‐breaking   technology  pla9orm  u0lizing  a  simple  blood  test  
  20. 20. The  CEE  Solu+on   Personalized  Medicine  from  a  Liquid  Biopsy